Twist Bioscience legal chief sells 1,099 shares

Twist Bioscience executive Dennis Cho reported a routine tax-related stock sale.

Rhea-AI Filing Summary

Twist Bioscience executive Dennis Cho reported a routine tax-related stock sale. On February 3, 2026, he sold 1,099 shares of Twist Bioscience common stock at $46.576 per share to cover tax withholding from vesting restricted stock units under the company’s equity plans.

After this mandated “sell to cover” transaction, Cho beneficially owned 143,581 shares of common stock in direct ownership. He serves as Senior Vice President, Chief Legal Officer & Corporate Secretary, and the filing notes these were not discretionary trades.

Insights

Equity compensation and insider-transactions analyst

Routine tax withholding sale; no thesis-changing signal.

The transaction shows Dennis Cho, a senior officer of Twist Bioscience, selling 1,099 common shares at $46.576 on February 3, 2026. A footnote explains this was to cover tax withholding on vesting restricted stock units under the company’s equity incentive plans.

Because the sale is mandated as a “sell to cover,” it does not represent a discretionary decision to reduce exposure. Cho still holds 143,581 shares directly afterward, indicating a substantial remaining stake. Overall, this appears as standard administration of equity compensation rather than a directional signal.

Insider Trade Summary

Net Seller: 1,099 shares

Net Sell 1 txn

Insider Cho Dennis

Role See Remarks

Sold 1,099 shs ($51K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,099	$46.576	$51K

Holdings After Transaction: Common Stock — 143,581 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

FAQ

What insider transaction did Twist Bioscience (TWST) officer Dennis Cho report?

Dennis Cho reported selling 1,099 shares of Twist Bioscience common stock. The sale occurred on February 3, 2026 at a price of $46.576 per share and was related to tax withholding on vesting restricted stock units, not a discretionary portfolio trade.

Why did Dennis Cho sell 1,099 Twist Bioscience (TWST) shares?

The 1,099 shares were sold to satisfy tax withholding obligations from vesting restricted stock units. The company’s equity plans require a mandated “sell to cover” transaction, so these sales are automatic for tax purposes and are not discretionary trading decisions by Dennis Cho.

How many Twist Bioscience (TWST) shares does Dennis Cho own after this Form 4?

After the reported transaction, Dennis Cho beneficially owned 143,581 shares of Twist Bioscience common stock. This figure reflects his direct holdings following the 1,099-share sale used to cover tax withholding tied to restricted stock unit vesting under the company’s equity incentive plans.

What role does Dennis Cho hold at Twist Bioscience (TWST)?

Dennis Cho serves as Senior Vice President, Chief Legal Officer & Corporate Secretary at Twist Bioscience. This officer role is indicated in the Form 4 remarks, showing he is a key member of the company’s executive leadership team with significant responsibilities for legal and corporate governance matters.

Was the Dennis Cho Twist Bioscience (TWST) stock sale a discretionary trade?

No. The filing states the shares represent a required sale to cover tax withholding on vesting restricted stock units. Under Twist Bioscience’s equity incentive plans, these “sell to cover” transactions are mandated by the issuer’s election and are not discretionary trades by Dennis Cho.

What transaction code is used for Dennis Cho’s Twist Bioscience (TWST) sale?

The Form 4 lists transaction code “S” for the February 3, 2026 trade in Twist Bioscience common stock. Code S designates an open-market or private sale, which in this case was executed solely to fund tax withholding obligations arising from vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Dennis

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2026		S		1,099(1)	D	$46.576	143,581	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.